Wall Street analyst estimates for IDEXX Laboratories, Inc. (IDXX): consensus price target, buy/hold/sell recommendations and forecasts for revenue and EPS for the upcoming fiscal years.
IDEXX Laboratories, Inc. is a global enterprise focused on creating, producing, and distributing a wide array of products and services. Its primary client base includes companion animal veterinary practices, the livestock and poultry industries, dairy operations, and water quality testing sectors.
Consensus price target
$692.33 (+3 % vs price $671.64)
between $627.00 and $740.00 · 3 targets published in the last quarter
Closing price, Nov 2
A twelve-month target is not a fair value: compare it with the range in the Valuation tab.
Revenue and EPS estimates
| Fiscal year | Revenue (average) | Revenue (low – high) | EPS (average) | Analysts |
|---|---|---|---|---|
| 2026E | $4.7B | $4.7B – $4.7B | $14.75 | 9 |
| 2027E | $5.1B | $5.1B – $5.2B | $16.74 | 10 |
| 2028E | $5.6B | $5.4B – $5.9B | $19.03 | 10 |
Figures in USD · consensus as of November 2, 2026
Analyst Consensus
| Strong Buy | 0 |
| Buy | 13 |
| Hold | 9 |
| Sell | 1 |
| Strong Sell | 0 |
| Total analysts | 23 |
| Avg rating (−2 sell to +2 buy) | 0.52 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2027-02-01 | $3.37 | ||
| 2026-11-02 | $3.96 | $3.73 | +6.2% |
| 2026-08-04 | $4.27 | $3.94 | +8.4% |
| 2026-05-05 | $3.47 | $3.41 | +1.8% |
| 2026-02-02 | $3.08 | $2.93 | +5.1% |
| 2025-11-03 | $3.40 | $3.14 | +8.3% |
| 2025-08-04 | $3.63 | $3.28 | +10.7% |
| 2025-05-01 | $2.96 | $2.85 | +3.9% |
Valuation Ratios
| P/E Ratio | 45.60 |
| Price / Book | 28.32 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.78B | $1.97B | $2.21B | $2.41B | $2.71B | $3.22B | $3.37B | $3.66B | $3.90B | $4.30B |
| Cost of Revenue | $800.0M | $871.7M | $971.7M | $1.04B | $1.14B | $1.33B | $1.36B | $1.47B | $1.52B | $1.64B |
| Gross Profit | $975.4M | $1.10B | $1.24B | $1.37B | $1.57B | $1.89B | $2.00B | $2.19B | $2.38B | $2.66B |
| Research & Development | $101.1M | $109.2M | $117.9M | $133.2M | $141.2M | $161.0M | $254.8M | $191.0M | $219.8M | $251.2M |
| Selling, General & Admin | $524.1M | $575.2M | $632.3M | $679.5M | $735.3M | $796.4M | $850.8M | $901.9M | $1.03B | $1.05B |
| Operating Expenses | $625.2M | $684.4M | $750.2M | $812.7M | $876.5M | $957.4M | $1.11B | $1.09B | $1.25B | $1.30B |
| Operating Income | $350.2M | $413.0M | $491.3M | $552.8M | $694.5M | $932.0M | $898.8M | $1.10B | $1.13B | $1.36B |
| EBITDA | $431.7M | $501.4M | $575.7M | $643.7M | $793.8M | $1.04B | $1.01B | $1.22B | $1.28B | $1.51B |
| Interest Expense | $32.0M | $37.2M | $34.7M | $31.1M | $33.1M | $29.8M | $39.9M | $41.6M | $31.2M | $38.3M |
| Pre-tax Income | $321.8M | $381.1M | $457.7M | $522.2M | $662.0M | $902.7M | $860.0M | $1.06B | $1.11B | $1.32B |
| Income Tax | $99.8M | $117.8M | $80.7M | $94.4M | $79.9M | $157.8M | $180.9M | $216.1M | $222.0M | $264.7M |
| Net Income | $222.0M | $263.1M | $377.0M | $427.7M | $581.8M | $744.8M | $679.1M | $845.0M | $887.9M | $1.06B |
| EPS | $2.47 | $3.00 | $4.34 | $4.97 | $6.82 | $8.74 | $8.12 | $10.17 | $10.77 | $13.17 |
| EPS (Diluted) | $2.44 | $2.94 | $4.26 | $4.89 | $6.71 | $8.60 | $8.03 | $10.06 | $10.67 | $13.08 |
| Shares Outstanding (Diluted) | 90.9 M | 89.6 M | 88.5 M | 87.5 M | 86.7 M | 86.6 M | 84.6 M | 84.0 M | 83.2 M | 80.7 M |
Price
| Price | $671.64 (closing price, November 2, 2026) |
| Market Cap | $52.9B |
| Exchange | NASDAQ |
| Country | US |
Related companies: MRK · ZTS · ELAN · TMO · 0R0H.L · DHR · 0R2B.L · NTRA
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of IDXX: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks